SCHEMBL6565628

SCHEMBL6565628

CCOC(=O)CSc1nc(Cl)cc(Nc2ccccc2)n1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 10/20 0.72
ALOX5 P09917 5/20 0.70
PPARG P37231 9/20 0.69
RXRA P19793 5/20 0.64
RXRG P48443 5/20 0.64
PPARD Q03181 3/20 0.64
RXRB P28702 4/20 0.59
ALDH1A1 P00352 3/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
KDM4E B2RXH2 1/20 0.54
ABCC4 O15439 1/20 0.54
ABCB11 O95342 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2D6 P10635 1/20 0.54
HPGD P15428 1/20 0.54
ALOX15 P16050 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
ABCB1 P08183 1/20 0.51
MAPK1 P28482 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6565546 0.94 ALOX5 (0.68) PPARAALOX5PPARGRXRARXRG
SCHEMBL6561975 0.91 ALOX5 (0.70) PPARAALOX5PPARGRXRARXRG
SCHEMBL6563923 0.89 ALOX5 (0.68) PPARAALOX5PPARGRXRARXRG
SCHEMBL6565607 0.88 ALOX5 (0.67) PPARAALOX5PPARGRXRARXRG
SCHEMBL6563313 0.86 ALOX5 (0.64) PPARAALOX5PPARGRXRARXRG
SCHEMBL6565495 0.83 PPARA (0.77) PPARAALOX5PPARGRXRARXRG
SCHEMBL11840409 0.82 ALOX5 (0.59) PPARAALOX5PPARGRXRARXRG
SCHEMBL6563326 0.82 ALOX5 (0.61) PPARAALOX5PPARGRXRARXRG
SCHEMBL6827151 0.81 KDM4E (0.58) ALOX5ALDH1A1MEN1KMT2AKDM4E
SCHEMBL6565776 0.80 L3MBTL1 (0.70) ALOX5ALDH1A1SMN1; SMN2ABCB1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1399426-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING BETA-AMYLOID PRODUCTION Active Pass Pharmaceuticals, Inc. (CA) 2004-03-24 EP disclosed
US-20030191144-A1 Compounds, compositions and methods for modulating beta-amyloid production ACTIVE PASS PHARMACEUTICALS, INC. (CA) 2003-10-09 US disclosed
US-20030125338-A1 Compounds, compositions and methods for modulating beta-amyloid production ACTIVE PASS PHARMACEUTICALS, INC. (CA) 2003-07-03 US disclosed
WO-2002100836-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING BETA-AMYLOID PRODUCTION ACTIVE PASS PHARMACEUTICALS, INC. (CA) 2002-12-19 WO disclosed
US-3940394-A ANTILIPEMIC SANTILLI ARTHUR A 1976-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125338-A1 Compounds, compositions and methods for modulating beta-amyloid production APP, PPARA, PPARG PPARA 2/4885ALOX5 197/4885PPARG 3/4885
US-20030191144-A1 Compounds, compositions and methods for modulating beta-amyloid production APP, PPARA, PPARG PPARA 2/4885ALOX5 197/4885PPARG 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.